Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)
Taiwan
· Delayed Price · Currency is TWD 78.80
-1.60 (-1.99%)
Dec 5, 2025, 1:30 PM CST
Gongwin Biopharm Holdings Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | -88.37 | -82.55 | -92.04 | -292.13 | -121.58 | -93.07 | Upgrade
|
| Depreciation & Amortization | 12.01 | 11.59 | 13.33 | 13.39 | 12.96 | 12.53 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 0 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -19.92 | -11.11 | - | - | -0.74 | -4.68 | Upgrade
|
| Stock-Based Compensation | - | 9.36 | - | 29.29 | 0.57 | 11.02 | Upgrade
|
| Provision & Write-off of Bad Debts | -0.51 | 5.91 | - | - | - | - | Upgrade
|
| Other Operating Activities | -4.42 | -17.11 | -10.16 | -4.83 | 4.36 | -8.16 | Upgrade
|
| Change in Accounts Receivable | 0.5 | -9.08 | -10.58 | - | - | - | Upgrade
|
| Change in Inventory | 5.32 | 8.34 | -11.72 | -0.21 | - | - | Upgrade
|
| Change in Accounts Payable | -0.49 | -0.08 | 0.29 | 11.72 | 2.83 | -0.79 | Upgrade
|
| Change in Unearned Revenue | 1.62 | - | 2.6 | 12.31 | 3.25 | - | Upgrade
|
| Change in Other Net Operating Assets | -10.16 | -2.69 | -2.52 | -1.72 | 2.84 | -4.11 | Upgrade
|
| Operating Cash Flow | -104.42 | -87.41 | -110.8 | -232.2 | -95.51 | -87.26 | Upgrade
|
| Capital Expenditures | -7.33 | -205.89 | -0.91 | -7.34 | -123.01 | -30.14 | Upgrade
|
| Sale (Purchase) of Intangibles | -0.5 | -0.24 | -0.22 | - | - | - | Upgrade
|
| Investment in Securities | 801.23 | -992.64 | -279.84 | -194.5 | -123.76 | 107.18 | Upgrade
|
| Other Investing Activities | 0.01 | 0.31 | - | -0.17 | 0.36 | - | Upgrade
|
| Investing Cash Flow | 793.41 | -1,198 | -280.97 | -202.01 | -246.42 | 77.05 | Upgrade
|
| Short-Term Debt Issued | - | 270.04 | 119.16 | 50.29 | 144.56 | 8.38 | Upgrade
|
| Total Debt Issued | 114.56 | 270.04 | 119.16 | 50.29 | 144.56 | 8.38 | Upgrade
|
| Short-Term Debt Repaid | - | -237.45 | -181.51 | -30 | -60.73 | - | Upgrade
|
| Long-Term Debt Repaid | - | -2.69 | -5.04 | -4.9 | -4.73 | -5.78 | Upgrade
|
| Total Debt Repaid | -111.87 | -240.14 | -186.55 | -34.9 | -65.46 | -5.78 | Upgrade
|
| Net Debt Issued (Repaid) | 2.69 | 29.9 | -67.39 | 15.4 | 79.11 | 2.6 | Upgrade
|
| Issuance of Common Stock | - | 1,989 | 11.95 | 575.42 | 22.66 | 538.83 | Upgrade
|
| Repurchase of Common Stock | -489.17 | -146.84 | - | - | - | - | Upgrade
|
| Other Financing Activities | -7.31 | 9.15 | 43.34 | 13.24 | 0 | - | Upgrade
|
| Financing Cash Flow | -493.8 | 1,881 | -12.1 | 604.05 | 101.77 | 541.43 | Upgrade
|
| Foreign Exchange Rate Adjustments | -5.07 | 24.31 | 5.94 | 47.55 | -12.96 | -13.68 | Upgrade
|
| Net Cash Flow | 190.12 | 619.88 | -397.92 | 217.39 | -253.11 | 517.54 | Upgrade
|
| Free Cash Flow | -111.75 | -293.3 | -111.7 | -239.54 | -218.52 | -117.4 | Upgrade
|
| Free Cash Flow Margin | -298.31% | -915.41% | -590.55% | -20956.69% | -19118.11% | -14093.16% | Upgrade
|
| Free Cash Flow Per Share | -0.90 | -2.43 | -0.99 | -2.15 | -2.00 | -1.12 | Upgrade
|
| Cash Interest Paid | 7.5 | 4.3 | 7.19 | 3.07 | 1.08 | 0.36 | Upgrade
|
| Cash Income Tax Paid | 0.15 | 0.08 | 0.04 | -0.05 | -0.16 | -0.07 | Upgrade
|
| Levered Free Cash Flow | -119.54 | -316.82 | -23.45 | -255.26 | -239.95 | -94.65 | Upgrade
|
| Unlevered Free Cash Flow | -116.56 | -314.14 | -18.96 | -253.27 | -239.21 | -94.33 | Upgrade
|
| Change in Working Capital | -3.22 | -3.51 | -21.92 | 22.1 | 8.92 | -4.9 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.